Biodexa Pharmaceuticals Plc (BDRX) - Dilution Analysis

20-F filing | 225817.8M shares outstanding

POS AM filing: This document is a POS AM filing that provides updates on various securities transactions and offerings by Biodexa Pharmaceuticals PLC, including registered direct offerings, warrant exercises, and equity line agreements.

POS AM filing: This POS AM filing outlines the expenses associated with the sale and distribution of securities being registered.

POS AM filing: This POS AM filing details the expenses associated with the sale and distribution of securities, totaling $75,904.

POS AM filing: This POS AM filing registers securities for sale, but the specific details of the offering, such as the proposed amount, number of shares, and price per share, are not defined at this time.

20-F filing | 6685.9M shares outstanding

F-1 filing: This F-1 filing outlines the expenses associated with the sale and distribution of securities, totaling $75,904, including SEC registration fees, printing, accounting, legal, and miscellaneous costs.

POS AM filing: This is a POS AM filing that describes February 2023 Private Placement and May 2023 Registered Direct Offering.

POS AM filing: This is a POS AM filing detailing previous offerings from October 2019 and May 2020 involving the sale of ordinary shares and warrants.

20-F filing | 1189.6M shares outstanding

F-1 filing: The company is offering Class A Units (Depositary Share and Series E Warrant) and Class B Units (Pre-Funded Warrant and Series E Warrant), as well as registering the Depositary Shares issuable upon exercise of the warrants.

POS AM filing: This is a POS AM filing providing details on previous offerings including the October 2019 and May 2020 offerings, including registered direct offerings and concurrent private placements of warrants.

F-1 filing: This is an F-1 filing detailing private placements, registered direct offerings, and warrant issuances, including descriptions of the terms, amounts, and shareholder approvals related to these transactions.

POS AM filing: This POS AM filing discusses the closing of a private placement and the issuance of warrants for ordinary shares.

POS AM filing: This POS AM filing discusses the completion of a private placement on February 15, 2023, involving the sale of Ordinary Shares represented by Depositary Shares and warrants, as well as subsequent shareholder approval for the issuance of shares under these warrants.

20-F filing | 5.4M shares outstanding

F-3 filing: This is an F-3 filing for Midatech Pharma PLC, allowing them to issue up to $25,000,000 of any combination of ordinary shares, American Depositary Shares representing ordinary shares, or warrants to purchase ordinary shares.

20-F filing | 98.5M shares outstanding

POS AM filing: This is a POS AM filing registering for resale shares underlying warrants issued in connection with previous registered direct offerings and concurrent private placements from October 2019 and May 2020.

POS AM filing: This is a POS AM filing related to previous offerings including October 2019 and May 2020 offerings.

20-F filing | 63.1M shares outstanding

F-1 filing: This is an F-1 filing including information on Ordinary Shares and Depositary Shares sold to institutional investors in registered direct offerings and placings in the United Kingdom, as well as warrants issued in private placements.